

SFA-002 Key Differentiators

1. Durable responses

This is not seen in any other drug. We have observed this in Phase 1a in long-term treatment.

2. Strong efficacy

Our PASI score is expected to approach 100 in long-term treatment. Most current drugs fall into two categories, either PASI (psoriasis area of severity) index scores of 75, or 95 - 100 with high SAE's. We expect to show high efficacy combined with an excellent safety profile.

3. Tolerability

Our drug has far fewer, if any, AE's compared to the current drugs.

4. Patient convenience

Our drug is oral and will be designed to be easy for patients to use.

5. Much improved Quality Of Life (QOL)

6. Value-based care

